Keywords: Mylan, HIV/AIDS treatments, WHO approval

WHO OKs Mylan 'Second-Line-in-a-Box' HIV/AIDS treatments

Article | 20 December 2011

US generic drugs major Mylan (Nasdaq: MYL) says its subsidiary Mylan Laboratories has received approval for three antiretroviral (ARV) therapies ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Mylan Laboratories

Go to company listing